Home / Business and Economy / Noom Undercuts Wegovy Price with Discounted Compounded Version
Noom Undercuts Wegovy Price with Discounted Compounded Version
4 Aug
Summary
- Noom selling compounded semaglutide (Wegovy generic) for $119 initially, rising to $199
- Novo Nordisk's Wegovy typically costs $1,349 per month in the U.S.
- FDA told compounding pharmacies to stop mass sales, but companies continue offering alternatives
As of August 4th, 2025, online weight-loss company Noom has announced it will sell a compounded version of Novo Nordisk's Wegovy weight-loss drug at an introductory price of $119 for up to a quarter of the branded drug's standard dose. After the first month, Noom's price for the generic semaglutide rises to $199 per month for a maximum 0.6-milligram dose, compared to Wegovy's typical 2.4 mg dose.
This move presents further price pressure for brand-name manufacturers, who have already been lowering prices to compete in the cash-pay weight-loss drug market. While few people pay Wegovy's $1,349 list price in the U.S., Novo Nordisk has offered a direct-to-consumer cash price of $499 per month for all doses up to 2.4 mg, and even promoted a first-fill price of $299 for some customers this month.
Noom's program aims to make the weight-loss medication more affordable and boost adherence by offering a lower dose that can mean fewer side effects. The company also continues to offer compounded versions of semaglutide at a maximum dose of 1.2 mg for $149 the first month and $279 afterward. This comes amid a shortage of Wegovy and Eli Lilly's Zepbound that prompted the FDA to allow compounding pharmacies to sell copies, though the agency has since told them to end mass sales. However, companies have continued to compound semaglutide, citing it as legal for treating patient needs not met by branded versions.
